A seasoned investment and operating executive with experience in private equity, growth equity and corporate M&A, Michael G. Hansen focuses on sourcing, diligencing and scaling companies across healthcare and technology sectors. He has led deal execution, portfolio company operational improvement and capital formation efforts; profile of a market-oriented investor bridging strategic operations and financial structuring for mid-market transactions.
A seasoned investment and operating executive with experience in private equity, growth equity and corporate M&A, Michael G. Hansen focuses on sourcing, diligencing and scaling companies across healthcare and technology sectors. He has led deal execution, portfolio company operational improvement and capital formation efforts; profile of a market-oriented investor bridging strategic operations and financial structuring for mid-market transactions.
Combines private equity rigor with operating-led value creation, prioritizing mid-market healthcare and technology businesses where operational improvements and product-led growth can unlock scale. Emphasizes deep due diligence, disciplined capital structuring, and active board-level involvement to drive margin expansion and commercial acceleration. Prefers growth-at-scale opportunities with clear pathways to margin improvement, recurring revenue models, and defensible technology or clinical differentiation; typically horizon of 3–7 years with calibrated downside protection and staged capital deployment tied to operational milestones.
Combines private equity rigor with operating-led value creation, prioritizing mid-market healthcare and technology businesses where operational improvements and product-led growth can unlock scale. Emphasizes deep due diligence, disciplined capital structuring, and active board-level involvement to drive margin expansion and commercial acceleration. Prefers growth-at-scale opportunities with clear pathways to margin improvement, recurring revenue models, and defensible technology or clinical differentiation; typically horizon of 3–7 years with calibrated downside protection and staged capital deployment tied to operational milestones.
| Trades 1960 | Longs Won 1335/1960 68% | Profit Factor 5.44 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $145,919.68 |
| Average Win $67,286.63 | Best Trade (Aug 14) $2.58M | Sharpe Ratio -10.04 |
| Average Loss -$26,412.67 | Worst Trade (Aug 25) -$985,082.07 | Z-Score 1.25 (79%) |
| Commissions $0 | Avg. Trade Length 1y 2d | Expectancy $36,685.43 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 12,658 | 11,392 | 10,127 | 8,861 | 7,595 | 6,329 | 5,063 | 3,797 | 2,532 | 1,266 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 19,121 | $4.71M | $5.91M | - | $1.2M | 25.46% | -7.354% |
ABBV AbbVie Inc. | 3,324 | $762,187.84 | $834,124.56 | - | $71,936.72 | 9.44% | -2.513% |
ABT Abbott Laboratories | 23,021 | $2.31M | $2.43M | - | $127,760.01 | 5.54% | +0.085% |
ACYN FT Vest Laddered Autocallable Barrier & Income ETF | 348,601 | $7.25M | $7.21M | - | -$34,903.33 | -0.48% | -0.097% |
ACYS FT Vest Laddered Autocallable Barrier & Resilient Income ETF | 12,702 | $260,900 | $260,009.94 | - | -$890.06 | -0.34% | -0.146% |
ADI Analog Devices, Inc. | 4,681 | $1.09M | $1.72M | - | $628,345.23 | 57.57% | +0.202% |
AFLG First Trust Active Factor Large Cap ETF | 91,041 | $3.19M | $4M | - | $819,008.05 | 25.71% | +0.503% |
AJG Arthur J. Gallagher & Co. | 9,216 | $2.42M | $2.3M | - | -$121,700.83 | -5.03% | -2.745% |
AMAT Applied Materials, Inc. | 1,550 | $529,812.6 | $786,888.52 | - | $257,075.92 | 48.52% | +1.176% |
AMD Advanced Micro Devices, Inc. | 2,601 | $1.51M | $1.24M | - | -$272,479.88 | -18.03% | -1.904% |
AMGN Amgen Inc. | 1,787 | $593,993.99 | $688,280.92 | - | $94,286.93 | 15.87% | -0.64% |
AMZN Amazon.com Inc | 23,100 | $4.86M | $6.27M | - | $1.41M | 28.97% | +15.321% |
ANGL VanEck Fallen Angel High Yield Bond ETF | 127,212 | $3.73M | $3.68M | - | -$49,560.72 | -1.33% | -0.035% |
AVGO Broadcom Inc. | 8,664 | $1.89M | $3.37M | - | $1.48M | 78.38% | +0.371% |
AZN AstraZeneca PLC American Depositary Shares | 10,885 | $2.15M | $1.85M | - | -$300,255.47 | -13.99% | -0.992% |
BAC Bank of America Corporation | 31,516 | $976,540.96 | $1.95M | - | $975,875.24 | 99.93% | +0.356% |
BBNX Beta Bionics Inc. | 10,000 | $170,000 | $128,300 | - | -$41,700 | -24.53% | -10.091% |
BGT BlackRock Floating Rate Income Trust | 20,000 | $255,200 | $216,600 | - | -$38,600 | -15.13% | +0.744% |
BIL SPDR Bloomberg 1-3 Month T-Bill ETF | 76,972 | $7.06M | $7.06M | - | -$4,758.71 | -0.07% | +0.033% |
BILS SPDR Bloomberg 3-12 Month T-Bill ETF | 13,253 | $1.32M | $1.32M | - | -$61.13 | - | +0.02% |